Gilead Sciences: Hypertension trials

The registry lists 19 Hypertension studies with Gilead Sciences as lead sponsor. 0 are open to participants now and 9 have results posted.

Phase 2 7Phase 3 11Phase 4 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Selonsertib in Adults With Pulmonary Arterial HypertensionCompletedNCT02234141Phase 2Results posted
• Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver DecompensationCompletedNCT01687257Phase 2Results posted
• ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary FibrosisTerminatedNCT00879229Phase 3Results posted
• Study of Ambrisentan in Participants With Pulmonary HypertensionCompletedNCT00777920Phase 3Results posted
• Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)CompletedNCT00617305Phase 4Results posted
• A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202)CompletedNCT00578786Phase 3Results posted
• Phase 2 Extension Study of Ambrisentan in Pulmonary Arterial HypertensionCompletedNCT00424021Phase 2Results posted
• Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial HypertensionCompletedNCT00423592Phase 2Results posted
• Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary HypertensionCompletedNCT00380068Phase 3Results posted
• Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)TerminatedNCT00832507Phase 2
• Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.CompletedNCT00423748Phase 3
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.CompletedNCT00423202Phase 3
• DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant HypertensionCompletedNCT00389779Phase 3
• DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant HypertensionTerminatedNCT00389675Phase 3
• A Clinical Study to Evaluate the Effects of Darusentan on Safety and Efficacy in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Blood Pressure Lowering DrugsCompletedNCT00364026Phase 2
• DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant HypertensionTerminatedNCT00353574Phase 3
• DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant HypertensionCompletedNCT00330369Phase 3
• ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH)CompletedNCT00091598Phase 3
• Study of BSF 208075 Evaluating Exercise Capacity in Patients With Pulmonary Arterial HypertensionCompletedNCT00046319Phase 2